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Abstract 
Objective: To evaluate the association between statin use and risk of biliary tract cancers 
(BTCs).   
Design: This is a nested case-control study based on the United Kingdom Clinical Practice 
Research Datalink (CPRD).  We included cases diagnosed with incident primary BTCs, 
including cancers of the gallbladder, bile duct (i.e., both intrahepatic and extrahepatic 
cholangiocarcinoma), ampulla of Vater, and mixed type, between 1990 and 2017.  For each case, 
we selected five controls who did not develop BTCs at the time of case diagnosis, matched by 
sex, year of birth, calendar time, and years of enrollment in the general practice using incidence 
density sampling.  A history of prescribed medications 1 year prior to diagnosis/selection was 
obtained from the patient prescription records.  Odds ratios (ORs) and 95% confidence intervals 
(CIs) for associations between statins and BTC overall and by subtypes were estimated using 
conditional logistic regression, adjusted for relevant confounders. 
Results: We included 3,118 BTC cases and 15,519 cancer-free controls.  Current statin use 
versus non-use was associated with a reduced risk of all BTCs combined (adjusted OR=0.88, 
95%CI: 0.79-0.98).  The reduced risks were most pronounced among long-term users, as 
indicated by increasing number of prescriptions (Ptrend = 0.016) and cumulative dose of statins 
(Ptrend = 0.008).  The magnitude of association was similar for statin use and risk of individual 
types of BTCs.  The reduced risk of BTCs associated with current statin use versus non-use was 
more pronounced among persons with diabetes (adjusted OR=0.72, 95%CI: 0.57-0.91). Among 
non-diabetics, the adjusted OR for current statin use versus non-use was 0.91 (95%CI: 0.81-1.03, 
Pheterogeneity=0.007).   
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Conclusion: We provide evidence that current, but not former, statin use was associated with a 
lower risk of BTCs compared with nonuse of statins.  If replicated, particularly in countries with 
a high incidence of BTCs, our findings could pave the way for evaluating the value of statins for 
BTC chemoprevention.   
Key words: ampulla of Vater cancer, biliary tract cancer, cholangiocarcinoma, CPRD, 
gallbladder cancer, statin 
Short summary 
1. What is already known about this subject? 
 Statins are commonly used cholesterol-lowering medications that have demonstrated 
effectiveness in the primary and secondary prevention of cardiovascular disease.  
 Several epidemiological studies have shown that statins are associated with a lower risk 
of gallstone disease (gallstones or a history of cholecystectomy), but associations with 
biliary tract cancers (BTCs) have not been well studied.     
2. What are the new findings? 
 There was significantly reduced risk of biliary tract cancers among current users of 
statins, as compared with non-users (odds ratio, 0.88).  
 The reduced risks were most pronounced among long-term users, as indicated by 
increasing number of prescriptions (P for trend = 0.016) and cumulative dose of statins 
(P for trend = 0.008).   
3. How might it impact on clinical practice in the foreseeable future? 
 Current or long-term statin use may reduce risk of biliary tract cancers.  
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 If replicated in other settings, the value of statins for BTC chemoprevention should be 
evaluated.   
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Introduction 
Biliary tract cancers (BTCs) are comprised of cancers of the gallbladder, bile duct (i.e., 
both intrahepatic and extrahepatic cholangiocarcinoma), and ampulla of Vater.  BTCs are rare 
but highly fatal diseases, with a median overall survival of ~12 months.[1]  Although the 
etiology of BTCs is largely unknown, the epidemiologic and molecular characteristics suggest 
that they are distinct disease entities.[1, 2]  For example, gallbladder cancer (GBC) is more 
common in women than men, while other BTCs are more common in men.[3]  Similarly, 
cirrhosis and infection with hepatitis B and C viruses are associated with intrahepatic 
cholangiocarcinoma, while their associations with GBC and ampulla of Vater cancer (AVC) are 
less clear.[1, 4] 
Despite these differences, BTCs share common risk factors.  For example, disorder of 
lipid regulation (i.e., hyperlipidemia) has been associated with an increased risk of cancer at all 
sites in the biliary tract.[5]  Hyperlipidemia is thought to interact with inflammation and pro-
inflammatory immune response to influence the risk of BTCs.[6, 7]  For GBC, local 
inflammation due to gallstones plays a central role,[8] while for cholangiocarcinoma, both 
intrahepatic and extrahepatic sclerosing cholangitis play a major role.[1]  Inflammation from 
biliary adenomas, which are seen in patients with familial adenomatous polyposis,[9] is thought 
to contribute to the 100-fold higher risk of AVC in that population.[10]  Finally, other causes of 
inflammation, such as bacterial infection and obesity/metabolic syndrome, may play a role in the 
etiology of BTC.[1]   
Given these strong ties with dyslipidemia and inflammation, statins (3-hydroxy-3-
methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) could potentially reduce the risk 
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of BTCs.  Statins are commonly used cholesterol-lowering medications that have demonstrated 
effectiveness in the primary and secondary prevention of cardiovascular disease.[11]  Several 
studies have shown that statins are associated with a lower risk of gallstone disease (gallstones or 
a history of cholecystectomy) [12, 13, 14, 15], but associations with BTCs have not been well 
studied.  To further our understanding of the associations between statins and BTCs, we thus 
conducted a nested case-control study within a large database of primary care electronic medical 
records – the United Kingdom (UK) Clinical Practice Research Datalink (CPRD).[16]  
Methods 
This study is based on data from the CPRD obtained under license from the UK 
Medicines and Healthcare products Regulatory Agency.  The data are provided by patients and 
collected by the national health service (NHS) as part of their care and support.  The 
interpretation and conclusions contained in this study are those of the authors alone.  The study 
was approved by the Independent Scientific Advisory Committee of the CPRD 
(proposal#17_160.R). 
Study Population and Design  
The UK CPRD was established in 1987 and contains information on ~8.5% (13.3 
million) of the UK population.  All data are provided by general practitioners; the CPRD 
population is representative of the general UK population.[17]  Detailed information includes 
demographic data, physician contacts, tests conducted, and medications prescribed.  Diagnoses, 
physical findings, symptoms, and administrative events, such as referrals to specialists, are 
recorded using Read codes, the standard clinical terminology system used in general practice in 
the UK.[18]    
 8 
In this nested case-control study, we included all persons whose most recent active 
registration at a CPRD practice overlapped with the study period from 1990 (three years after the 
establishment of the database) through 2017.  Entry date was defined as the patient's current 
registration date (i.e., the later of the practice's up-to-standard date), and exit date was defined as 
the date of cancer diagnosis/selection, death, leaving the practice, or last collection of data from 
the practices, whichever occurred first.  Eligible cases included persons aged 21-100 years with a 
first cancer diagnosis (except non-melanoma skin cancer) of BTC (Read codes provided in 
Supplementary Table 1) identified in CPRD during 1990-2017.  To ascertain statin use, we 
excluded the 1-year period prior to cancer diagnosis to minimize the possibility of reverse 
causation (i.e., incipient cancer leading to statin use); therefore, the index date was defined as the 
date of BTC diagnosis minus one year.  All cases were required to have at least one year of 
recorded activity in the CPRD prior to the index date (i.e., two years total of enrollment were 
required). 
 Five controls per case were randomly selected using incidence density sampling.  
Controls were individually matched on sex, year of birth (+/−3 years), index year (+/−3 years), 
and number of years in the general practice and in the CPRD prior to index date.  All controls 
were required to be alive and cancer-free (except for non-melanoma skin cancer) prior to the 
diagnosis date of the matched case and were required to have at least one year of enrollment in 
the CPRD participating practice prior to the case index date (i.e., the date of BTC diagnosis 
minus one year; thus, two years total of enrollment were required).  Selected controls with exit 
date before entry were excluded (N=55).  
Ascertainment of Statins and Covariates 
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 A history of prescribed medications prior to the index date was obtained from the patient 
prescription records.  Drugs of interest included statins, other lipid-lowering agents (i.e., bile acid 
sequestrant, cholesterol absorption inhibitor, fibrate, nicotinic acid derivative, Omega-3 fatty 
acid, and Bis-phenol antioxidant), treatment for type 2 diabetes (i.e., metformin, insulin, 
Acetohexamide, Tolbutamide, Chlorpropamide, Glibenclamide, Glibornuride, Gliclazide, 
Rosiglitazone, Tolazamide, and Tolbutamide), aspirin, and cortisone, which were included 
because of their potential effect on metabolism.  Statin use was defined as having two or more 
statin prescriptions recorded, and nonuse of statins was defined as having 0-1 prescriptions.[19]  
Former statin use was defined as use ending more than one year prior to the index date.  Use 
ending within one year prior to the index date was considered as current use.  Based on the 
distribution among controls, statin use was classified by time since first recorded statin use (0-2, 
3-5, 6-8, and 9+ years), number of prescriptions (2-15, 16-35, 36-65, and 66+, representing 
approximate duration of use) and cumulative dose (quartiles), which was defined as number of 
pills multiplied by the dose per pill.  This grouping strategy permitted examination of the trend 
for the association of increasing statin use with risk for BTCs.  Finally, specific commonly used 
statins (atorvastatin, simvastatin, pravastatin, and rosuvastatin) were examined individually. 
 Because body mass index (BMI), smoking, alcohol drinking, diabetes mellitus, 
gallstones, cirrhosis, hepatitis virus infection, chronic heart disease, and dyslipidemia may be 
associated with both statin use and BTCs or BTCs at specific subsites, we identified persons who 
had these conditions prior to the index date.  We also assessed healthy user effect, healthy 
adherer effect, and functional status prior to the index date because these factors have been 
suggested as important confounders in observational studies (Supplementary Materials).[20]   
Statistical analyses 
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We used conditional logistic regression to estimate odds ratios (ORs) for the association 
of statins with BTCs overall and with individual types (i.e., GBC, cholangiocarcinoma, and 
AVC).  The regression model included adjustment for known BTC risk factors: BMI, smoking 
status, alcohol drinking status, and a history of diabetes.[21]  GBC-specific analyses excluded 
177 controls with a history of cholecystectomy because those controls were not at risk for 
developing GBC, and history of gallstones was additionally included in the model.  
Cholangiocarcinoma-specific analyses additionally included history of cirrhosis in the model. 
Other potential confounders were selected if they changed the adjusted OR for BTC and 
statin use status by more than 10%.  We first considered a fully adjusted model that included all 
potential confounders: a history of hepatitis virus infection, chronic heart disease, dyslipidemia, 
high exercise, healthy diet, cancer screening, influenza vaccination, pneumonia, dementia, 
comorbidity, and use of treatment for type 2 diabetes, aspirin, cortisone, or other lipid-lowering 
agents.  However, additional adjustment for those variables resulted in only marginal changes in 
the ORs (Supplementary Table 2); such adjustments were therefore not included in the final 
model.  We also selected covariates by mutually entering all potential confounders into a 
stepwise logistic regression model, with P<0.15 as the model entry criterion and P<0.05 for a 
variable to remain in the model.  Likewise, adjustment for variables selected resulted in OR 
changes of less than 10% (Supplementary Table 2).  We thus only present results from the 
minimally adjusted model.  We tested for linear trends across statin use categories with the Wald 
test using categorical values of the number of prescriptions and cumulative dose with 1 degree of 
freedom. 
 We evaluated potential effect modification by matching variables (i.e., sex, age at index 
date [≤70 versus >70 years; the age cutoff was chosen to create two equally large age groups 
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among the control subjects, among whom the median age was 72 years], and index year [≤2004 
versus >2004 because 10 mg of simvastatin became available over-the-counter in August 2004] 
[22]).  Likelihood ratio tests were used to compare models with and without an interaction term 
between statin use and each potential modifier.  Because statin use has been associated with 
increased risk of diabetes,[23, 24, 25] we conducted a joint analysis of diabetes and statin use 
initiated before or after diabetes diagnosis.  We used patients with diabetes who did not use 
statins as the reference group for a model focused on the potential protective effect of statins on 
BTCs among patients with diabetes; this model was additionally adjusted for treatment for type 2 
diabetes.  We then reran the model using non-diabetic patients who did not use statins as the 
reference group to focus on the effect of former or current statin use among non-diabetics. 
 In sensitivity analyses, we focused on incident statin users (defined as those with the first 
recorded use of statins of ≥5 years after entry into CPRD) to limit the effect of confounding (i.e., 
intended and unintended treatment effects) and yield results closer to those that would be seen in 
randomized clinical controlled trial.[26]  We also conducted analyses excluding 145 cases with 
carcinoma in situ of the biliary system and their matched controls, excluding subjects with non-
biliary cancer in situ (i.e., all carcinoma in situ except that of the biliary system) since diagnosis 
of in situ cancer may have led to lifestyle changes, or excluding subjects with missing/unknown 
information on smoking, alcohol drinking, and BMI.  Finally, although information on treatment 
is not complete in the CPRD because this information is reported by primary care physicians 
only, not specialists, cases with supporting clinical codes that indicated presence of BTCs such 
as diagnostic exams (biopsies), treatment (chemotherapy, radiotherapy, surgery), palliative care, 
and referrals to specialty care were considered as confirmed BTCs.  
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Statistical analyses were performed using R Statistical Software (Foundation for 
Statistical Computing, Vienna, Austria).  All statistical tests were 2-sided, and P<0.05 was 
considered statistically significant. 
Results 
 Table 1 shows the distribution of demographic characteristics and other potential risk 
factors.  A total of 3,118 BTC cases (708 GBC, 1678 cholangiocarcinoma, 228 AVC, 500 mixed, 
4 unknown) and 15,519 cancer-free controls were included (Table 1).  By design, cases and 
controls were individually-matched on sex, age, index year, and years in the CPRD participating 
practice prior to the index date. Cases were more likely to be obese; be current smokers; drink 
alcohol; have a history of chronic diseases, including diabetes, gallstones, and cirrhosis; be 
infected with hepatitis viruses; have treatment for type 2 diabetes; and use aspirin or cortisone. 
Controls were more likely to be diagnosed with dementia. 
 Table 2 shows adjusted ORs for statin use and risk of all BTCs combined.  Although 
former statin use was not associated with BTC risk, current use versus non-use was associated 
with a reduced risk of BTCs (adjusted OR=0.88, 95%CI: 0.79-0.98, Table 2).  Individuals who 
started using statins nine or more years before the index date had reduced risk of BTCs 
(OR=0.85, 95%CI: 0.72-1.01), but the trend was not consistent across increasing categories of 
time since first statin use (Ptrend=0.128).  Although there was some evidence of a dose-response 
trend with increasing number of prescriptions (Ptrend=0.016) and cumulative dose of statins 
(Ptrend=0.008), the trend was not consistent across all categories, and only the highest quartile 
(Q4) compared with nonuse of statins was statistically significant.  For example, compared with 
nonuse of statins, the adjusted OR of the highest quartile (Q4) for cumulative dose was 0.81 
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(95%CI: 0.68-0.96).  We did not observe heterogeneity by type of statin but had limited 
statistical power for individual types of statins (Supplementary Table 3). 
 The reduced risk associated with statin use was similar for individual types of BTCs 
(Table 3).  For example, the adjusted ORs for current statin use versus nonuse and risk of GBC, 
cholangiocarcinoma, and AVC were 0.86 (95%CI: 0.67-1.09), 0.87 (0.75-1.01), and 0.89 (0.59-
1.34), respectively.  There were no clear dose-response relationships between risk of individual 
types of BTCs and number of prescriptions and cumulative dose, but the ORs were of similar 
magnitude to those for BTCs overall.  
 The observed associations were similar for men and women, for individuals ≤70 and >70 
years of age at index date, and for those with an index year of ≤2004 and >2004 (all 
Pheterogeneity>0.05, Supplementary Table 4).  In the joint analysis by history of diabetes, we 
found that statin use was associated with a lower risk of BTCs among patients with diabetes, 
with an adjusted OR for current statin use versus non-use of 0.72 (95%CI: 0.57-0.91).  Among 
non-diabetics, the adjusted OR for current statin use versus non-use was 0.91 (95%CI: 0.81-1.03. 
Pheterogeneity=0.007).  The reduced risk of BTCs was more pronounced among participants with 
statins prescribed before diabetes was diagnosed (adjusted OR=0.59, 95%CI: 0.44-0.81) than 
among those with statins prescribed after diabetes was diagnosed (0.84 [0.66-1.08], 
Pheterogeneity=0.03).   
 In sensitivity analyses, the adjusted ORs remained stable in patients with incident current 
statin use (OR=0.81, 95%CI: 0.70-0.94), excluding persons with biliary carcinoma in situ and 
their controls (OR for current statin use=0.88, 95%CI: 0.79-0.98), and among cases and controls 
without a history of cancer in situ except carcinoma in situ of biliary system (0.89, 95%CI: 0.79-
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0.99) or without missing/unknown status for smoking, alcohol drinking, and BMI (0.90, 95%CI: 
0.80-1.02).  
Discussion 
In this large study, we observed a reduced risk of BTCs among current statin users 
compared to nonusers.  Reduced risk of BTCs was also more pronounced among subjects with 
the highest number of prescriptions and cumulative dose of statins, suggesting that long-term 
statin users may have a lower risk of developing BTCs.  The risk estimate was consistent across 
individual types of BTCs, age groups, sex, and calendar time.  Adjustment for various risk 
factors did not substantively alter the results.  Finally, we also observed a risk reduction among 
persons with diabetes.  If replicated in other studies, these findings suggest that statins may have 
a role as chemopreventive agents.   
Comparison to other studies 
To our knowledge, this study is the first to address the association between statin use and 
risk of cancer across the biliary tract.  Our findings are in line with the one previous study 
focusing on one individual type of BTC (cholangiocarcinoma) in Taiwan, which reported that the 
adjusted OR for statin use versus nonuse for cholangiocarcinoma was 0.80 (95%CI: 0.71-
0.90).[27]  The results are also consistent with studies that have demonstrated a decreased risk of 
gallstone disease,[12, 13, 14, 15] a risk factor for BTCs,[28] especially GBC.[1, 2]  Statins could 
potentially reduce risk of BTCs through suppression of biliary cholesterol secretion and 
saturation and anti-inflammatory and endothelial effects.[29, 30] The reduction in hepatic and 
gallbladder bile cholesterol concentrations could alter bile acid composition and interfere with 
gallstone production or even promote gallstone dissolution.[31]  In addition, both experimental 
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and clinical studies provide evidence that statins have anti-inflammatory effects.[29, 30]  Statins 
reduce circulating C-reactive protein and pro-inflammatory cytokines and chemokines.[32, 33] 
Statins also favorably affect important pathways regulating nitric oxide bioavailability, which is 
critical for maintaining endothelium homeostasis via statins’ vasodilatory, anti-inflammatory, 
and overall anti-atherogenic effects.  In addition, statins have been shown to regulate expression 
of many inflammatory genes.[30]  Associations between statin use and lower risk of cancers 
related to inflammation, including cancers of the colorectum [34, 35] and esophagus [36, 37, 38], 
have been reported in epidemiological studies.  However, we did not observe a joint effect of use 
of both statins and aspirin (data not shown), as has been reported for cancer of the esophagus 
[37, 38].  
Our findings of reduced BTC risk among persons with diabetes using statins should be 
interpreted with caution.  Some studies suggest that statins may increase the risk of diabetes, 
although results are inconsistent.[23, 24]  Experimental data support the hypothesis that statins 
may cause diabetes by altering glucose homeostasis through both impaired insulin secretion and 
diminished insulin sensitivity.[39]  Following this hypothesis, statins could increase the risk of 
BTCs by increasing risk of diabetes.  However, in the present study, we observed a reduced risk 
of BTCs among persons with diabetes who used statins before their diabetes was diagnosed, as 
compared with those with diabetes who did not use statins.  Lipophilic (simvastatin and 
atorvastatin) and hydrophilic (pravastatin and rosuvastatin) statins have been observed to have 
different diabetogenic effects,[40] but we lacked the power to investigate whether the observed 
reduced risk of BTCs was driven by specific types of statins.  Additional studies are needed to 
clarify the associations between statins, diabetes, and BTCs, but overall our results suggest that 
statins reduce the risk of BTCs both in patients with diabetes and those without.   
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 Our study has several strengths.  First, it was conducted using a large, well-established, 
validated, longitudinal primary-care database with long-term follow-up.  This database is known 
for accuracy of diagnoses, including cancer, and completeness of pharmacy data.[41, 42]  
Second, all information on diseases and drug exposures in the CPRD is recorded prior to BTC 
diagnosis and in the absence of a study hypothesis, reducing the risk of recall bias.  Third, we 
could evaluate the impact of various important confounders (BMI, smoking, alcohol drinking, a 
history of diabetes, hepatitis virus infection, chronic heart disease, dyslipidemia, and use of 
treatment for type 2 diabetes, aspirin, cortisone, or other lipid-lowering agents); such information 
is usually not accessible in registry-based studies.  Although we did not adjust for socioeconomic 
status (SES), SES has been not associated with statin prescribing in England.[43]  In addition, 
cases and controls were matched on general practice, and the universal health care coverage in 
the UK may, to some degree, control for SES.  Finally, we conducted a large number of 
sensitivity analyses that further support the robustness of our findings.  
Our study has a few limitations.  First, although our sample size was sufficient for all 
BTCs combined, power was limited for individual types of BTCs and individual statins.  Second, 
compliance rates among persons taking statins could not be evaluated, leading to potential 
exposure misclassification.  Third, although we adjusted for several factors, these conditions 
could be incompletely captured in the database; residual confounding is possible even after our 
adjustment.  For example, our adjustment for confounding by healthy user effect, healthy adherer 
effect, and functional status or cognitive impairment, which are not usually considered in 
observational studies,[20] did not change the magnitude of the association between statin use and 
risk of BTCs.  Fourth, although previous validation studies have reported that cancer diagnoses 
are accurate and complete,[41, 44] the diagnosis of BTCs in the present study was not verified 
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and misclassification cannot be ruled out.  Further studies conducted in databases with validated 
cancer diagnosis are warranted.  Fifth, use of statins may not be completely captured after 2004 
because 10mg simvastatin became available over-the-counter at that time, and a previous study 
showed a decreased trend in statin prescribing since 2004.[22]  We conducted a stratified 
analysis by calendar year but did not observe significant heterogeneity in the association before 
and after 2004.  It is also likely that this misclassification occurs equally for cases and controls 
and thus is nondifferential by case-control status.  If true, this misclassification could 
underestimate the strength of the reduced risk of BTCs associated with use of statins.  Finally, 
we cannot rule out a potential role of chance given the number of tests evaluated with the 
potential for false positives. 
 In conclusion, this large observational study provides evidence that current or long-term 
statin use is associated with decreased risk of BTCs.  Our findings should be replicated in other 
populations, particularly in high-risk areas, such as Chile, to confirm our observations and 
further establish the potential value of statins for BTC chemoprevention.   
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Table 1. Characteristics of cases with biliary tract cancer and controls, CPRD a 
Characteristic Case (n=3,118) Control (n=15,519) P value 
Cancer site (n, %)   -- 
   Gallbladder 708 (22.7) --  
   Bile duct 1678 (53.8) --  
   Ampulla of Vater 228 (7.3) --  
   Mixed 500 (16.0) --  
   Missing 4 (0.1) --  
Index year (n, %)    
   1989-1999 369 (11.8) 1836 (11.8) -- 
   2000-2004 633 (20.3) 3149 (20.3)  
   2005-2009 884 (28.4) 4422 (28.5)  
   2010-2016 1232 (39.5) 6112 (39.4)  
Years in CPRD prior to index date      
   Mean ± SD 22.4 ± 17.0 22.6 ± 17.0 -- 
Age at index date, years (n, %)    
   20-49 525 (16.8) 2607 (16.8) -- 
   50-69 756 (24.2) 3822 (24.6)  
   70-79 1010 (32.4) 5026 (32.4)  
   80-99 827 (26.5) 4064 (26.2)  
   Mean ± SD 71.0 (11.9) 71.0 (11.8)  
Sex (n, %)   -- 
   Male 1439 (46.2) 7156 (46.1) -- 
   Female 1679 (53.8) 8363 (53.9)  
Body mass index, kg/m2 (n, %)    
   <18.5 (low) 28 (0.9) 168 (1.1) <0.001 
   18.5–24.9 (normal) 853 (27.4) 4788 (30.9)  
   25.0–29.9 (overweight) 1102 (35.3) 5120 (33.0)  
   30.0+ (obese) 650 (20.8) 2577 (16.6)  
   Missing/Unknown  485 (15.6) 2866 (18.5)  
Smoking status (n, %)    
   Never 618 (19.8) 3472 (22.4) <0.001 
   Former 1484 (47.6) 7340 (47.3)  
   Current 764 (24.5) 2964 (19.1)  
   Missing/Unknown  252 (8.1) 1743 (11.2)  
Alcohol drinking status (n, %)    
   Never 458 (14.7) 2339 (15.1) 0.002 
   Former 131 (4.2) 548 (3.5)  
   Current 2022 (64.8) 9709 (62.6)  
 22 
   Missing/Unknown  507 (16.3) 2923 (18.8)  
Chronic disease history (n, %)    
   Diabetes 15 (0.5) 11 (0.1) <0.001 
   Gallstone 29 (0.9) 34 (0.2) <0.001 
   Cirrhosis 234 (7.5) 480 (3.1) <0.001 
   Hepatitis virus infection 127 (5.3) 546 (4.5) 0.138 
   Cholecystectomy b 677 (21.7) 3171 (20.4) 0.113 
   Chronic heart disease 481 (15.4) 2540 (16.4) 0.203 
   Dyslipidemia 458 (14.7) 1648 (10.6) <0.001 
Prescription drug use history (n, %)    
   Treatment for Type 2 diabetes 330 (10.6) 1234 (8.0) <0.001 
   Aspirin 1070 (34.3) 4927 (31.7) 0.002 
   Cortisone 925 (29.7) 4032 (26.0) <0.001 
   Other lipid-lowering agents 134 (4.3) 594 (3.8) 0.236 
Healthy user effect (n, %)     
   High exercise 26 (0.8) 186 (1.2) 0.097 
   Healthy diet 633 (20.3) 2989 (19.3) 0.188 
Healthy adherer effect (n, %)     
   Cancer screening 672 (21.6) 3152 (20.3) 0.123 
   Influenza vaccination 398 (12.8) 1916 (12.3) 0.537 
Functional status or cognitive impairment (n, %)     
   Pneumonia 101 (3.2) 500 (3.2) 1.000 
   Dementia 33 (1.1) 336 (2.2) <0.001 
   Comorbidity 155 (5.0) 673 (4.3) 0.128 
a Excludes 55 controls with entry date after exit date. 
b Excludes 708 cases with gallbladder cancer and their 3,508 matched controls. 
 
 
  
 23 
Table 2. Association between statin use and biliary tract cancers, CPRD 
Characteristic Case (n=3,118) 
Control 
(n=15,519) 
Adjusted OR 
(95% CI) a 
Any statin use    
   Nonusers 2159 (69.2) 10934 (70.5) ref. 
   Ever 959 (30.8) 4585 (29.5) 0.92 (0.83, 1.02) 
       Former b 199 (6.4) 831 (5.4) 1.10 (0.92, 1.31) 
       Current 760 (24.4) 3754 (24.2) 0.88 (0.79, 0.98) 
Time since first statin use 
recorded (years)    
   Nonusers 2159 (69.2) 10934 (70.5) ref. 
   0-2 206 (6.6) 1064 (6.9) 0.87 (0.74, 1.02) 
   3-5 292 (9.4) 1316 (8.5) 0.98 (0.84, 1.13) 
   6-8 233 (7.5) 1060 (6.8) 0.97 (0.82, 1.14) 
   9+ 228 (7.3) 1145 (7.4) 0.85 (0.72, 1.01) 
P trend   0.128 
No. of prescriptions    
   Nonusers 2159 (69.2) 10934 (70.5) ref. 
   2-15 254 (8.1) 1169 (7.5) 0.98 (0.84, 1.14) 
   16-35 236 (7.6) 1144 (7.4) 0.92 (0.79, 1.08) 
   36-65 252 (8.1) 1089 (7.0) 1.00 (0.85, 1.17) 
   66+ 217 (7.0) 1183 (7.6) 0.76 (0.64, 0.91) 
P trend   0.016 
Cumulative dose c    
   Nonusers 2159 (69.2) 10934 (70.5) ref. 
   Q1 269 (8.6) 1146 (7.4) 1.07 (0.93, 1.24) 
   Q2 225 (7.2) 1147 (7.4) 0.85 (0.73, 1.00) 
   Q3 242 (7.8) 1147 (7.4) 0.90 (0.77, 1.06) 
   Q4 223 (7.2) 1144 (7.4) 0.81 (0.68, 0.96) 
   Missing 0 1  
P trend   0.008 
Abbreviation: CI, confidence interval; Q, quartile; OR, odds ratios 
a Adjusted for body mass index, smoking, alcohol drinking, and diabetes 
b Former: Stopped using statins 1+ years before index date 
c Q1=13175, Q2=32480, Q3=65520 
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Table 3. Association between statin use and subsites of biliary tract cancer, CPRD a 
Characteristic 
Gallbladder b   Bile duct c   Ampulla of Vater 
Case 
(n=708) 
Control 
(n=3331) 
Adjusted OR 
(95% CI)  
Case 
(n=1678) 
Control 
(n=8322) 
Adjusted OR 
(95% CI)  
Case 
(n=228) 
Control 
(n=1125) 
Adjusted OR 
(95% CI) a 
Any statin use            
   Nonusers 495 (69.9) 2374 (71.3) ref.  1167 (69.5) 5880 (70.7) ref.  162 (71.1) 802 (71.3) ref. 
   Ever 213 (30.1) 957 (28.7) 0.89 (0.71, 1.11)  511 (30.5) 2442 (29.3) 0.92 (0.80, 1.05)  66 (28.9) 323 (28.7) 0.96 (0.66, 1.41) 
       Former 49 (6.9) 198 (5.9) 1.01 (0.69, 1.48)  106 (6.3) 426 (5.1) 1.14 (0.89, 1.45)  17 (7.5) 65 (5.8) 1.30 (0.68, 2.46) 
       Current 164 (23.2) 759 (22.8) 0.86 (0.67, 1.09)  405 (24.1) 2016 (24.2) 0.87 (0.75, 1.01)  49 (21.5) 258 (22.9) 0.89 (0.59, 1.34) 
Time since first 
statin use recorded 
(years) 
           
   Nonusers 495 (69.9) 2374 (71.3) ref.  1167 (69.5) 5880 (70.7) ref.  162 (71.1) 802 (71.3) ref. 
   0-2 41 (5.8) 195 (5.9) 0.84 (0.57, 1.24)  110 (6.6) 572 (6.9) 0.82 (0.66, 1.04)  14 (6.1) 82 (7.3) 0.74 (0.39, 1.41) 
   3-5 63 (8.9) 297 (8.9) 0.85 (0.61, 1.19)  160 (9.5) 691 (8.3) 1.02 (0.84, 1.25)  15 (6.6) 81 (7.2) 0.88 (0.47, 1.63) 
   6-8 60 (8.5) 228 (6.8) 1.08 (0.76, 1.54)  125 (7.4) 569 (6.8) 0.97 (0.78, 1.22)  14 (6.1) 82 (7.3) 0.86 (0.45, 1.65) 
   9+ 49 (6.9) 237 (7.1) 0.79 (0.54, 1.17)  116 (6.9) 610 (7.3) 0.82 (0.65, 1.05)  23 (10.1) 78 (6.9) 1.68 (0.89, 3.15) 
P trend   0.391    0.246    0.433 
No. of prescriptions            
   Nonusers 495 (69.9) 2374 (71.3) ref.  1167 (69.5) 5880 (70.7) ref.  162 (71.1) 802 (71.3) ref. 
   2-15 54 (7.6) 227 (6.8) 0.98 (0.69, 1.39)  136 (8.1) 642 (7.7) 0.93 (0.76, 1.15)  19 (8.3) 83 (7.4) 1.02 (0.58, 1.81) 
   16-35 47 (6.6) 248 (7.4) 0.76 (0.53, 1.09)  133 (7.9) 608 (7.3) 0.97 (0.79, 1.20)  18 (7.9) 71 (6.3) 1.20 (0.66, 2.15) 
   36-65 60 (8.5) 242 (7.3) 0.97 (0.69, 1.36)  136 (8.1) 568 (6.8) 1.04 (0.83, 1.29)  14 (6.1) 81 (7.2) 0.80 (0.42, 1.54) 
   66+ 52 (7.3) 240 (7.2) 0.84 (0.58, 1.24)  106 (6.3) 624 (7.5) 0.71 (0.55, 0.90)  15 (6.6) 88 (7.8) 0.77 (0.39, 1.50) 
P trend   0.306    0.063    0.498 
Cumulative dose d            
   Nonusers 495 (69.9) 2374 (71.3) ref.  1167 (69.5) 5880 (70.7) ref.  162 (71.1) 802 (71.3) ref. 
   Q1 62 (8.8) 240 (7.2) 1.08 (0.78, 1.49)  145 (8.6) 635 (7.6) 1.02 (0.83, 1.25)  15 (6.6) 77 (6.8) 0.92 (0.51, 1.65) 
   Q2 52 (7.3) 239 (7.2) 0.88 (0.62, 1.25)  114 (6.8) 598 (7.2) 0.83 (0.66, 1.04)  22 (9.6) 81 (7.2) 1.30 (0.74, 2.31) 
   Q3 44 (6.2) 239 (7.2) 0.66 (0.45, 0.97)  139 (8.3) 601 (7.2) 1.00 (0.81, 1.24)  10 (4.4) 82 (7.3) 0.67 (0.33, 1.36) 
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   Q4 55 (7.8) 238 (7.1) 0.91 (0.62, 1.32)  113 (6.7) 608 (7.3) 0.79 (0.62, 1.00)  19 (8.3) 83 (7.4) 0.97 (0.51, 1.85) 
P trend   0.141    0.081    0.739 
Abbreviation: CI, confidence interval; Q, quartile; OR, odds ratio 
a ORs are adjusted for body mass index, smoking, alcohol drinking, and diabetes. 
b ORs are additionally adjusted for gallstones.  Excludes 177 controls with a history of cholecystectomy. 
c ORs are additionally adjusted for cirrhosis. 
d For gallbladder cancer, Q1=14560, Q2= 34720, Q3= 66080; for cancer in Bile duct, Q1= 13440, Q2= 32480, Q3= 66080; for cancer of Ampulla of Vater, Q1= 12320, Q2=33600, 
Q3=63840. 
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Supplementary Materials  
Identification of indicators of healthy user effect, healthy adherer effect, and functional status 
We assessed healthy user effect, healthy adherer effect, and functional status prior to the index 
date because these factors have been suggested as important confounders in observational 
studies.[1]  We used high exercise (i.e., Readcodes for active/intermediate/heavy exercise or 
exercises ≥1 time per work) and healthy diet (i.e., Readcodes for healthy diet, vegetarian diet, 
low cholesterol diet, gluten free diet, high fiber diet, low fat diet, or low salt diet) as indications 
of healthy users, participation in cancer screening and influenza vaccination as indications of 
healthy adherers, and pneumonia, dementia, and certain comorbidities (i.e., organ failure 
including respiratory system, heart, liver, and kidney) as indications of functional status.  
Reference 
1  Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies 
of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546‐50. 
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Supplementary Table 1. Read codes used to identify biliary tract cancers, CPRD 
Cancer site medcode readcode readterm 
Gallbladder cancer    
 16105 B160.00 Malignant neoplasm of gallbladder 
 31393 B160.11 Carcinoma gallbladder 
 46594 B808300 Carcinoma in situ of gall bladder 
Cholangiocarcinoma    
 8711 BB5D100 [M]Cholangiocarcinoma 
 40438 BB5D111 [M]Bile duct carcinoma 
 41313 BB5D300 [M]Bile duct cystadenocarcinoma 
 110775 B151100 Malignant neoplasm of interlobular biliary canals 
 89593 B151200 Malignant neoplasm of intrahepatic biliary passages 
 16915 B151.00 Malignant neoplasm of intrahepatic bile ducts 
 61643 B151z00 Malignant neoplasm of intrahepatic bile ducts NOS 
 99580 B808100 Carcinoma in situ of intrahepatic bile ducts 
 58088 B151400 Malignant neoplasm of intrahepatic gall duct 
 65124 B151000 Malignant neoplasm of interlobular bile ducts 
 23433 B161.00 Malignant neoplasm of extrahepatic bile ducts 
 74896 B161z00 Malignant neoplasm of extrahepatic bile ducts NOS 
 36495 B161211 Carcinoma common bile duct 
 7982 B161200 Malignant neoplasm of common bile duct 
 52537 B161100 Malignant neoplasm of hepatic duct 
 37501 B808200 Carcinoma in situ of hepatic duct 
 64089 B808500 Carcinoma in situ of common bile duct 
 72445 B161000 Malignant neoplasm of cystic duct 
Ampulla of Vater cancer   
 10949 B162.00 Malignant neoplasm of ampulla of Vater 
 21792 B808600 Carcinoma in situ of ampulla of Vater 
 105613 B161300 Malignant neoplasm of sphincter of Oddi 
Mixed    
 54103 B16.00 Malignant neoplasm gallbladder and extrahepatic bile ducts 
 15907 B16z.00 Malignant neoplasm gallbladder/extrahepatic bile ducts NOS 
 60312 B16y.00 Malignant neoplasm other gallbladder/extrahepatic bile duct 
 38978 B15z.00 Malignant neoplasm of liver and intrahepatic bile ducts NOS 
 8918 B15..00 Malignant neoplasm of liver and intrahepatic bile ducts 
 35039 B163.00 Malignant neoplasm, overlapping lesion of biliary tract 
 54103 B16..00 Malignant neoplasm gallbladder and extrahepatic bile ducts 
 70516 BB5D.11 [M]Biliary tract adenomas and adenocarcinomas 
 107299 BB5D700 [M]Combined hepatocellular carcinoma and cholangiocarcinoma 
 110147 BB5D711 [M]Hepatocholangiocarcinoma 
 36031 BB5D.00 [M]Hepatobiliary tract adenomas and carcinomas 
3 
 66673 B808.00 Carcinoma in situ of liver and biliary system 
 51934 B808.11 Carcinoma in situ of biliary system 
  98540 B808z00 Carcinoma in situ of liver or biliary system NOS 
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Supplementary Table 2. Association between statin use and biliary tract cancers, CPRD 
Characteristic Case (n=3,118) 
Control 
(n=15,519) 
Stepwise selection 
Adjusted OR 
(95% CI) a 
Fully  
Adjusted OR 
(95% CI) b 
Any statin use     
   Nonusers 2159 (69.2) 10934 (70.5) ref. ref. 
   Ever 959 (30.8) 4585 (29.5) 0.92 (0.81, 1.03) 0.91 (0.81, 1.03) 
       Former c 199 (6.4) 831 (5.4) 1.07 (0.89, 1.29) 1.06 (0.88, 1.29) 
       Current 760 (24.4) 3754 (24.2) 0.88 (0.78, 1.00) 0.88 (0.78, 1.00) 
Time since statin 
use firstly recorded 
(years)     
   Nonusers 2159 (69.2) 10934 (70.5) ref. ref. 
   0-2 206 (6.6) 1064 (6.9) 0.86 (0.72, 1.02) 0.85 (0.72, 1.02) 
   3-5 292 (9.4) 1316 (8.5) 0.97 (0.83, 1.14) 0.96 (0.82, 1.13) 
   6-8 233 (7.5) 1060 (6.8) 0.97 (0.81, 1.16) 0.96 (0.80, 1.15) 
   9+ 228 (7.3) 1145 (7.4) 0.87 (0.71, 1.05) 0.86 (0.70, 1.04) 
P trend   0.266 0.232 
No. of prescriptions     
   Nonusers 2159 (69.2) 10934 (70.5) ref. ref. 
   2-15 254 (8.1) 1169 (7.5) 0.95 (0.81, 1.12) 0.94 (0.80, 1.11) 
   16-35 236 (7.6) 1144 (7.4) 0.91 (0.77, 1.08) 0.90 (0.76, 1.07) 
   36-65 252 (8.1) 1089 (7.0) 0.99 (0.83, 1.18) 0.98 (0.82, 1.17) 
   66+ 217 (7.0) 1183 (7.6) 0.78 (0.64, 0.95) 0.77 (0.64, 0.94) 
P trend   0.048 0.043 
Cumulative dose d     
   Nonusers 2159 (69.2) 10934 (70.5) ref. ref. 
   Q1 269 (8.6) 1146 (7.4) 1.05 (0.89, 1.23) 1.04 (0.88, 1.22) 
   Q2 225 (7.2) 1147 (7.4) 0.85 (0.71, 1.01) 0.84 (0.71, 1.01) 
   Q3 242 (7.8) 1147 (7.4) 0.89 (0.75, 1.06) 0.89 (0.75, 1.06) 
   Q4 223 (7.2) 1144 (7.4) 0.82 (0.67, 0.99) 0.81 (0.67, 0.98) 
   Missing 0 1   
P trend   0.017 0.015 
Abbreviation: CI, confidence interval; Q, quartile; OR, odds ratios 
a Adjusted for BMI, smoking, alcohol drinking, hepatitis virus infection, cirrhosis, gallstone, 
dyslipidemia, diabetes, Aspirin, cortisone, high exercise, and dementia. 
b Adjusted for BMI, smoking, alcohol drinking, hepatitis virus infection, cirrhosis, gallstone, chronic 
heart disease, dyslipidemia, diabetes, Aspirin, cortisone, other lipid regulation drug, high exercise, 
health diet, pneumonia, cancer screening, influenza vaccination, dementia, and comorbidity. 
c Former: Stopped using statins 1+ years before index date 
d Q1=13175, Q2=32480, Q3=65520 
5 
Supplementary Table 3. Association between statin use and biliary tract cancers overall and by subtype, CPRD a 
Characteristic 
Biliary tract cancers overall   Gallbladder b   Bile duct   Ampulla of Vater 
Case 
(n=3,118) 
Control 
(n=15,519) 
Adjusted OR 
(95% CI)  
Case 
(n=708) 
Control 
(n=3331) 
Adjusted OR 
(95% CI)  
Case 
(n=1678) 
Control 
(n=8322) 
Adjusted OR 
(95% CI)  
Case 
(n=228) 
Control 
(n=1125) 
Adjusted OR 
(95% CI) 
Type of statin                
Nonusers 2159 (69.2) 10934 (70.5) ref.  171 (24.2) 763 (22.9) ref.  408 (24.3) 1988 (23.9) ref.  162 (71.1) 802 (71.3) ref. 
Simvastatin 764 (24.5) 3696 (23.8) 0.92 (0.83, 1.02)  77 (10.9) 384 (11.5) 0.89 (0.70, 1.12)  195 (11.6) 930 (11.2) 0.91 (0.79, 1.04)  52 (22.8) 258 (22.9) 0.93 (0.63, 1.39) 
Atorvastatin 361 (11.6) 1789 (11.5) 0.88 (0.78, 1.01)  25 (3.5) 100 (3.0) 0.84 (0.63, 1.12)  57 (3.4) 321 (3.9) 0.94 (0.79, 1.13)  29 (12.7) 126 (11.2) 1.15 (0.70, 1.87) 
Pravastatin 111 (3.6) 553 (3.6) 0.91 (0.74, 1.13)  16 (2.3) 59 (1.8) 1.01 (0.62, 1.65)  27 (1.6) 139 (1.7) 0.81 (0.60, 1.10)  10 (4.4) 33 (2.9) 1.64 (0.76, 3.54) 
Rosuvastatin 57 (1.8) 260 (1.7) 0.98 (0.72, 1.33)  2 (0.3) 25 (0.8) 1.08 (0.57, 2.02)  13 (0.8) 69 (0.8) 0.87 (0.57, 1.33)  6 (2.6) 17 (1.5) 1.73 (0.65, 4.60) 
Abbreviation: CI, confidence interval; OR, odds ratios 
a Adjusted for body mass index, smoking, alcohol drinking, and diabetes. 
b Odds ratios are additionally adjusted for gallstones.  Excludes 177 controls with a history of cholecystectomy. 
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Supplementary Table 4. Association between statin use and biliary tract cancers, stratified by sex, age at index date and index year, CPRD a 
 
Characteristic 
Sex  Age at index date (years)  Index year 
Male  Female P heterogeneity  ≤ 70  >70 
P 
heterogeneity  ≤2004  >2004 
P 
heterogeneity 
No. of 
cases/controls 
Adjusted OR 
(95% CI)  
No. of 
cases/controls 
Adjusted OR 
(95% CI)   
No. of 
cases/controls 
Adjusted OR 
(95% CI)  
No. of 
cases/controls 
Adjusted OR 
(95% CI)   
No. of 
cases/controls 
Adjusted OR 
(95% CI)  
No. of 
cases/controls 
Adjusted OR 
(95% CI)  
Any statin use      0.3       0.345       0.953 
  Nonusers 929/4790 ref.  1230/6144 ref.   1085/5475 ref.  1074/5459 ref.   907/4521 ref.  1252/6413 ref.  
  Former 98/364 1.34 (1.03, 1.74)  101/466 0.94 (0.74, 1.20)   53/229 1.03 (0.74, 1.42)  146/601 1.13 (0.91, 1.40)   10/57 0.79 (0.39, 1.59)  189/773 1.14 (0.94, 1.37)  
  Current 412/2002 0.94 (0.81, 1.09)  348/1752 0.83 (0.71, 0.97)   254/1285 0.85 (0.71, 1.01)  506/2469 0.90 (0.79, 1.03)   85/406 0.86 (0.66, 1.12)  675/3348 0.89 (0.79, 1.00)  
No. of 
prescriptions      0.273       0.463       0.997 
  Nonusers 929/4790 ref.  1230/6144 ref.   1085/5475 ref.  1074/5459 ref.   907/4521 ref.  1252/6413 ref.  
  2-15 134/581 1.09 (0.88, 1.35)  120/587 0.87 (0.70, 1.08)   91/469 0.85 (0.67, 1.09)  163/699 1.07 (0.88, 1.30)   47/227 0.86 (0.61, 1.21)  207/941 1.00 (0.84, 1.19)  
  16-35 117/571 0.95 (0.76, 1.20)  119/573 0.89 (0.71, 1.11)   92/432 0.95 (0.74, 1.22)  144/712 0.90 (0.74, 1.11)   26/139 0.79 (0.51, 1.23)  210/1005 0.94 (0.79, 1.12)  
  36-65 139/594 1.06 (0.85, 1.32)  113/495 0.94 (0.75, 1.19)   76/344 0.92 (0.70, 1.22)  176/745 1.03 (0.85, 1.26)   16/73 0.87 (0.49, 1.52)  236/1016 1.02 (0.86, 1.20)  
  66+ 120/620 0.85 (0.67, 1.08)  97/563 0.69 (0.53, 0.88)   48/269 0.73 (0.52, 1.04)  169/914 0.78 (0.63, 0.95)   6/24 1.08 (0.43, 2.71)  211/1159 0.77 (0.65, 0.92)  
P trend  0.433   0.012    0.112   0.065    0.339   0.039  
Cumulative 
dose      0.366       0.566       0.577 
  Nonusers 929/4790 ref.  1230/6144 ref.   1085/5475 ref.  1074/5459 ref.   907/4521 ref.  1252/6413 ref.  
  Q1 133/553 1.15 (0.93, 1.43)  136/593 1.00 (0.81, 1.23)   90/420 0.98 (0.76, 1.25)  179/726 1.13 (0.94, 1.36)   61/279 0.93 (0.69, 1.26)  208/867 1.11 (0.94, 1.32)  
  Q2 123/576 0.97 (0.78, 1.22)  102/571 0.75 (0.59, 0.95)   78/401 0.83 (0.63, 1.08)  147/746 0.87 (0.71, 1.07)   25/131 0.75 (0.48, 1.18)  200/1016 0.87 (0.73, 1.04)  
  Q3 136/622 0.98 (0.78, 1.22)  106/525 0.83 (0.66, 1.05)   73/382 0.81 (0.61, 1.08)  169/765 0.95 (0.78, 1.16)   7/47 0.65 (0.29, 1.46)  235/1100 0.93 (0.79, 1.10)  
  Q4 118/615 0.84 (0.66, 1.07)  105/529 0.79 (0.62, 1.02)   66/311 0.86 (0.63, 1.17)  157/833 0.79 (0.64, 0.98)   2/6 1.22 (0.24, 6.21)  221/1138 0.83 (0.69, 0.99)  
P trend  0.188   0.976    0.841   0.193    0.634   0.218  
Abbreviation: CI, confidence interval; OR, odds ratios 
a Adjusted for body mass index smoking, alcohol drinking, and diabetes 
 
 
